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Abstract 
The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex and 
expensive tests. In many cases, however, the diagnosis remains difficult despite the array of 
sophisticated diagnostic tests.  There is no ‘gold standard’ reference test. Hence, a task force 
supported by the European Respiratory Society has developed this guideline to provide evidence-
based recommendations on diagnostic testing, especially in the light of new developments in such 
tests, and the need for robust diagnoses of patients who might enter randomised controlled trials of 
treatments. The guideline is based on pre-defined questions relevant for clinical care, a systematic 
review of the literature, and assessment of the evidence using the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluation) approach. It focuses on: clinical 
presentation, nasal nitric oxide, analysis of ciliary beat frequency and pattern by high-speed video-
microscopy analysis, transmission electron microscopy, genotyping and immunofluorescence. It then 
used a modified Delphi survey to develop an algorithm for the use of diagnostic tests to definitively 
confirm and exclude the diagnosis of PCD; also to provide advice when the diagnosis is not 
conclusive. Finally, this guideline proposes a set of quality criteria for future research on the validity 
of diagnostic methods for PCD.   
  
Introduction 
PCD represents a clinical and genetic heterogeneous group of respiratory ciliopathies, with reduced 
muco-ciliary clearance of the airways. The various mutations result in different clinical and 
pathological patterns, contributing to the challenges of diagnosis.   There is no single gold standard 
diagnostic test for primary ciliary dyskinesia (PCD) [1]; current diagnosis requires a combination of 
technically demanding investigations, including nasal nitric oxide (nNO), high-speed video 
microscopy analysis (HSVA) and transmission electron microscopy (TEM). Historically clinicians used 
the saccharine test to screen for PCD, but this is no longer advocated [2]. Furthermore, more 
sophisticated diagnostic tests that might improve diagnostic accuracy (genotyping, 
immunofluorescence (IF) of ciliary proteins and EM tomography) are becoming increasingly 
available. 
The availability of tests varies across Europe [3]; this has partially improved recently in response to 
collaborations including a former Task Force(2006-9) of the European Respiratory Society (ERS) [2–4] 
and FP-7 funded BESTCILIA. The ERS Task Force published a consensus statement in 2009 [2] to 
guide diagnostic testing and BESTCILIA has recently introduced diagnostic testing into three 
countries where services did not previously exist.  Since the 2009 statement, a number of groups 
and consortia have investigated the accuracy of various diagnostic tests for PCD, providing the 
opportunity to advance the state of diagnostics by developing evidence based guidelines.  Therefore, 
in 2014 a new PCD ERS Task Force consisting of adult and paediatric physicians from pulmonology 
and ENT disciplines along with diagnostic scientists was established; it aimed to develop evidence 
based guidelines for the diagnosis of PCD. This is important for the appropriate clinical management 
and prognosis of individual patients with suspected or eventually confirmed PCD; to ensure patients 
with PCD are correctly diagnosed whilst avoiding the problems of false positive diagnoses. It should 
also ensure a definitive diagnosis before PCD patients are enrolled in randomised controlled clinical 
trials of treatment. 
  
Methods 
The methods are described in detail in the supplementary file. 
Task Force Composition 
In brief, the panel consisted of a multidisciplinary group of clinicians and scientists with recognised 
expertise in the diagnosis of primary ciliary dyskinesia; junior members/ trainees affiliated to 
European PCD centres were active members of the committee (Supplementary Table 1). 
Methodologists from the ERS provided expertise in guideline development following the GRADE 
approach for diagnostic tests [5]. Panel members disclosed potential conflicts of interest according 
to ERS policies at the start of the Task Force and prior to publication of this manuscript.  
Patient-Important Outcomes 
The GRADE approach emphasizes the importance of recommendations based on the impact on 
patient-important outcomes [6]. The patient representatives to the Task Force fully endorsed that 
an accurate diagnosis was an important outcome, because it leads to a better recognition of their 
problems by physicians and more effective treatment, and thus improves their health and quality of 
life.   This was confirmed by our questionnaire survey of 352 PCD patients from 25 countries, and 20 
in-depth interviews [7]. However, diagnostic accuracy studies do not provide direct evidence for the 
improvement of patient-important outcomes; consequently, the confidence in results of test 
accuracy studies was judged at best as moderate. 
Formulation of the Topics and Questions  
The Task Force members agreed that six facets of PCD diagnostics should be evaluated: clinical 
symptoms, nNO, HSV, TEM, genotype and IF labelling of ciliary proteins. We evaluated each test to 
see whether it should be included in the diagnostic pathway for PCD, using a ‘PICO’ structured 
question: “Patients suspected of having PCD, Investigated by [nNO, TEM etc], when Comparing 
patients with a final positive or negative diagnostic outcome, what was the diagnostic accuracy 
(Outcome) of the test?” The PICO questions for each test were finalised during several rounds of 
teleconferences and email discussions (Supplementary Table 2).   
The essential inclusion criterion for studies was that they must have included consecutive patients 
referred for PCD testing, in whom the PCD diagnosis was then either confirmed or excluded; we 
excluded studies if patients had already had previous diagnostic testing. In the absence of such 
studies, in the narrative review we discussed case control studies which compared PCD patients with 
healthy controls, or with patients suffering from other respiratory diseases (e.g. CF).  . Results from 
such studies cannot be generalised to the clinical situation, where patients with PCD must be 
distinguished from patients referred for similar complaints, but without PCD. Thus, the results from 
case control studies are far less relevant for clinical care.  The main limitation for this project was the 
lack of a gold standard diagnostic test for PCD. In the absence of this, we compared the diagnostic 
performance indicators (e.g. sensitivity and specificity) to the authors’ final decision regarding 
positive/negative PCD diagnosis based on all available tests.  
The Task Force also agreed on a list of less structured questions relevant to PCD diagnostics for the 
narrative discussion. As the evidence for these questions were not formally graded, they were not 
used for recommendations.  
Literature Search Methods 
We searched Medline and Embase databases (accessed through Ovid) from 1st January 1996 to 14th 
March 2016. Full details are provided in the supplementary file. In brief, titles and abstracts were 
screened; the full text was then reviewed for papers which potentially fulfilled criteria for inclusion. 
These manuscripts were checked for completeness by the Task Force panel to ensure all data 
fulfilling the a priori inclusion criteria were present. PRISMA flow diagrams show the search process 
for each WG (supplementary file figure 1).  
Quality of Evidence and Strength of Recommendations  
We used the GRADE approach through the entire process, from grading the quality of evidence, to 
deciding on the strength of the recommendations [8, 9]. Full details are provided in the 
supplementary file including reasons for downgrading the confidence in the evidence (summary of 
evidence tables)Recommendations were made based on the strength of evidence and other factors 
such as overall accuracy of the test (sensitivity and specificity), confidence in the net accuracy (range 
of sensitivity/sensitivity from included studies and/or confidence intervals of net sensitivity and 
specificity) and considerations such as patient acceptability of the test, feasibility of testing and how 
accessible the test is.  The four tests where evidence based recommendations were made, were all 
acceptable to the patient, feasible and acceptable.” Consensus statement for confirming 
or excluding PCD 
We used a modified Delphi survey to reach a consensus regarding the use of diagnostic tests to 
definitively confirm and exclude the diagnosis of PCD; also to provide advice regarding patients who 
do not have a definitive diagnosis but diagnostic tests suggest that the diagnosis is highly likely or 
inconclusive. The methods are detailed in the on-line supplementary file.  
  
Results 
The results of the evidence assessment gave rise to the recommendations in Table 1. 
Recommendations 
 
Which patients should be referred for diagnostic testing?  
Based on MODERATE confidence in the evidence: 
1. We recommend that patients are tested for PCD if they have severali of the following 
features: persistent wet cough; situs anomalies; congenital cardiac defects; persistent 
rhinitis; chronic middle ear disease with or without hearing loss; a history in term infants 
of neonatal upper and lower respiratory symptoms or neonatal intensive care admittance  
(strong recommendation).  
2. Patients with normal situs presenting with symptoms suggestive of PCD (as listed in 
recommendation 1) should be referred for diagnostic testing (strong 
recommendation).  
3. Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive 
of PCD (as listed in recommendation 1) (strong recommendation).  
4. We suggest the use of combinations of distinct PCD symptoms and predictive tools (e.g. 
PICADAR) to identify patients for diagnostic testing (weak recommendation).  
 
In patients suspected of having PCD, should nasal nitric oxide be used as a diagnostic tool? 
Based on MODERATE confidence in the evidence, we recommend that:  
1. Nasal nitric oxide measurement should be used as part of the diagnostic work-up of 
schoolchildren over 6 years and adults suspected of having PCD, preferably using a 
chemiluminescence analyser with a velum closure technique (strong recommendation).   
2. In children under 6 years suspected of having PCD, we suggest nasal nitric oxide 
measurement using tidal breathing as part of the diagnostic work-up (weak 
recommendation).  
Remark - we suggest that patients presenting with a strong clinical history should undergo 
further testing, even if nNO is normal (weak recommendation). 
 
 
In patients suspected of having PCD, should HSVA be used as a diagnostic tool? 
Based on LOW confidence in the evidence, we recommend: 
1. High speed video analysis, including ciliary beat frequency and beat pattern analysis, 
should be used as part of the diagnostic work-up of patients suspected of having PCD 
(weak recommendation).  
2. Ciliary beat frequency should not be used without assessment of ciliary beat pattern in 
diagnosing PCD (strong recommendation). 
3. To improve diagnostic accuracy of HSVA, CBF/P assessment should be repeated after ALI 
culture (strong recommendation). 
 
In patients suspected of having PCD, should TEM be used as a diagnostic tool? Based on LOW 
confidence in the evidence, we recommend: 
1. Ciliary ultrastructure analysis by transmission electron microscopy should be used as part 
of the diagnostic work-up of patients suspected of having PCD (strong recommendation). 
2. Further diagnostic investigations should be performed in patients with normal 
ultrastructure if the clinical history is strong (strong recommendation).2 
3. In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory 
diagnostic investigations are not required3. (strong recommendation). 
 
In patients suspected of having PCD, should genotyping be used as a diagnostic tool? 
There were no studies that fulfilled inclusion criteria to answer this question.    
 
Statements to assist the clinician are made in the genetics sections but these are NOT evidence 
based. 
 
In patients suspected of having PCD, should IF be used as a diagnostic tool? 
There were no studies that fulfilled inclusion criteria to answer this question.    
 
Statements to assist the clinician are made in the IF sections but these are NOT evidence based. 
Table 1. Evidence-based recommendations for the use of each of the six tests considered for PCD 
diagnosis. 1 Available evidence does not allow to be more specific; minimum number depends on the 
type of symptoms; 2normal ciliary ultrastructure, as resolvable by transmission electron microscopy, 
does not exclude the diagnosis of PCD (16% PCD positive patients have TEM without a detectable 
defect); 3patients with hallmark ciliary ultrastructure defects for PCD (absence of outer dynein arms, 
combined absence of inner and outer dynein arms, inner dynein arm absence combined with 
microtubular disarrangement), assessed by TEM, almost always have PCD (false positive results are 
very rare ≈0.7%)  
Clinical features 
Summary of recommendations 
Which patients should be referred for diagnostic testing?  
Based on MODERATE confidence in the evidence: 
1. We recommend that patients are tested for PCD if they have several1 of the following 
features: persistent wet cough; situs anomalies; congenital cardiac defects; persistent 
rhinitis; chronic middle ear disease with or without hearing loss; a history in term infants of 
neonatal upper and lower respiratory symptoms or neonatal intensive care admittance  
(strong recommendation).  
2. Patients with normal situs presenting with symptoms suggestive of PCD (as listed in 
recommendation 1) should be referred for diagnostic testing (strong recommendation).  
3. Siblings of patients should be tested for PCD, particularly if they have symptoms suggestive 
of PCD (as listed in recommendation 1) (strong recommendation).  
Footnote: 1 Available evidence does not allow to be more specific; minimum number depends on the 
type of symptoms. 
Review of evidence directly addressing the question “in patients suspected of having PCD, which 
clinical features predict a positive diagnosis”? 
Our search identified 1269 studies of which two directly answered the question and were included 
in the quantitative synthesis (Supplementary Figure 1) and an additional 6 contributed to the 
narrative review. We excluded 1217 publications based on titles and abstracts. After full text review 
we excluded 44 of the remaining 52 studies because they did not fulfil the inclusion criteria 
(Supplementary table 3). 
Two studies, Behan et al [10] and Shapiro et al[11], were suitable to provide evidence for our 
recommendations. They included 1408 patients (Table 2).  
 
Clinical Manifestation Sensitivity (95% C.I.) Specificity (95% C.I.) 
Neonatal manifestations 
Neonatal chest symptoms 0.75 (0.63-0.84) 0.83 (0.79-0.84) 
Neonatal rhinitis 0.27 (0.17-0.38) 0.94 (0.91-0.95) 
Neonatal respiratory support 0.41 (0.30-0.53) 0.93 (0.90-0.95) 
Neonatal unit admission 0.61 (0.49-0.72) 0.86 (0.83-0.89) 
Upper respiratory manifestations after the postnatal period 
Chronic rhinitis 0.81 (0.70-0.89) 0.43 (0.38-0.47) 
Chronic serous otitis media 0.57 (0.45-0.69) 0.81(0.77-0.84) 
Chronic acute otitis media 0.33 (0.23-0.45) 0.75 (0.71-0.79) 
Hearing loss 0.49 (0.38-0.61) 0.84 (0.81-0.87) 
Chronic ear perforation 0.12 (0.06-0.22) 0.91 (0.88-0.93) 
Ear surgery 0.32 (0.22-0.44) 0.86 (0.82-0.88) 
Chronic sinusitis 0.28 (0.19-0.40) 0.76 (0.72-0.79) 
Lower respiratory manifestations after the postnatal period 
Chronic wet cough 0.93 (0.84-0.98) 0.15 (0.12-0.18) 
Recurrent wheeze 0.48 (0.36-0.60) 0.62 (0.57-0.65) 
Previous pneumonia 0.41 (0.30-0.53) 0.65 (0.61-0.69) 
Bronchiectasis 0.29 (0.20-0.41) 0.68 (0.64-0.72) 
Other manifestations (various ages) 
Situs anomalies** 0.51 (0.46-0.56)  0.94 (0.92-0.95) 
Congenital heart disease 0.08 (0.03-0.17) 0.98 (0.97-0.99) 
Developmental delay 0.11 (0.05-0.20) 0.94 (0.91-0.96) 
Hydrocephalus 0.01 (0.00-0.08) 0.99 (0.98-1.00) 
Subfertility* 0.91 (0.57-1.00) 0.82 (0.74-0.87) 
Family history (any age) 
Of PCD in siblings 0.24 (0.15-0.35) 0.98 (0.97-0.99) 
Of PCD in extended family 0.05 (0.02-0.14) 0.99 (0.97-1.00) 
Of asthma 0.16 (0.09-0.27) 0.66 (0.62-0.70) 
Of bronchiectasis 0.04 (0.01-0.12) 0.96 (0.93-0.97) 
Of otitis media 0.07 (0.02-0.16) 0.89 (0.86-0.92) 
Clinical scores  
PICADAR (score>5) 0.90 (0.81-0.96) 0.75 (0.70- 0.80) 
Table 2. Summary of reported clinical manifestations in studies included in the quantitative analysis. 
All data from Behan et al (641 eligible referrals, 75 (12%) had PCD)[10] but data on subfertility* are 
from a subgroup of 152 referrals where 11 (7%) had PCD). Data on situs anomalies** are from Behan 
et al and Shapiro et al (767 referrals) [11]. 
 
Behan et al analysed data from 868 consecutive paediatric and adult patients [10]. Those with 
inconclusive or incomplete results (227) were excluded, leaving 641 for analysis. All patient data  
were collected through a proforma completed by a clinician prior to the diagnostic testing. They 
reported sensitivity and specificity of a large range of clinical features (Table 2 and Supplementary 
Table 3). Wet cough did not discriminate well between PCD positive and negative patients 
(sensitivity 0.93, specificity 0.15), because it was the main reason for referral, so was present in 
virtually all patients. Neonatal chest symptoms and neonatal rhinitis had a high specificity (0.83 and 
0.94), but a lower sensitivity (0.27 and 0.75). The sensitivity and specificity for 25 clinical features are 
summarised in Table 2 and described in detail in the supplementary file. 
In addition to reporting on single symptoms, Behan et al developed a 7-point questionnaire-based 
prediction tool (PICADAR), to help predict the likelihood that a patient referred for evaluation of 
persistent wet cough has PCD. PICADAR was internally and externally (in a second cohort) validated 
and is the first clinical prediction tool developed for PCD. The score ranged from 0 to 14; sensitivity 
and specificity of a score of >5 were 0.90 and 0.75 respectively; clearly better than single symptoms.  
Shapiro et al analysed data from 767 consecutive paediatric and adult patients[11]. Information on 
situs was determined by physicians at local consortium sites through review of radiology, surgery, 
and cardiology reports and radiology images from participant medical records. Patients were divided 
into 3 situs categories: situs solitus, situs inversus and situs ambiguous (including heterotaxy). 
Situs abnormalities were reported by Behan and Shapiro for a total of 1048 patients. The  pooled 
sensitivity for the two papers (for any situs abnormality) was 0.508 and specificity 0.939 
(Supplementary Table 3). 
Narrative review of additional evidence 
Leigh et al described a prospective cohort of 534 children with high suspicion of PCD, among whom  
many had a pre-existing diagnosis of PCD.  Experts defined a priori and tested 5 clinical features, 
apparent in early childhood, and found 4 to be alone or in combination predictive of PCD: (1) 
unexplained neonatal respiratory distress with supplemental oxygen requirement more than 24 
hours in term infants; (2) early-onset, year-round, wet cough; (3) early-onset, year-round nasal 
congestion; and (4) laterality defects [12].  Noll et al described a retrospective cohort of 323 patients 
with chronic cough referred for ciliary function analyses, and reported high specificity (>0.9) for 
neonatal respiratory distress (NRDS), persistent otitis media, situs inversus and bronchiectasis[13].  
Chin et al reviewed retrospectively records of 118 patients referred for electron microscopy because 
of suspected PCD, and compared combinations of symptoms between patients with abnormal and 
normal EM, while excluding uncertain cases. They found more sino-nasal, middle ear and pulmonary 
symptoms in the abnormal group [11]. Beucher et al compared patients with abnormal and normal 
EM in a retrospective cohort of 89 children suspected of PCD, excluding 21 uncertain cases and 
found that only situs inversus differed significantly between the groups[14]. Pifferi et al compared 
clinical symptoms in 98 patients with primary PCD versus secondary ciliary dyskinesia; statistically 
significant differences were found for situs inversus and severity of bronchiectasis [15]. Mullowney 
et al , in the only publication that focused on neonates, compared neonatal symptoms between 46 
PCD patients and 46 controls with a history of NRDS[16], and found that lobar collapse, situs 
inversus and prolonged oxygen need were more common in infants with PCD. The combination of 
situs inversus, lobar collapse, or oxygen need for >2 days had 87% (95% CI 74–94) sensitivity and 
96% (85–99) specificity for PCD.  A systematic review by Goutaki et al describes other case-control or 
case series studies on prevalence of clinical symptoms in PCD, which do not fulfil the inclusion 
criteria for this study [17]. All studies are from developed countries, and it is probable that the 
predictive value of some symptoms would be different depending on geographical region; for 
example, sensitivity and specificity of bronchiectasis will be different in sub-Saharan Africa where 
bronchiectasis due to TB is common.  
Key unanswered questions and research needs 
Further research is needed using prospective cohort studies of patients referred with suspicion of 
PCD, in whom clinical features are assessed in a standardised way before they are diagnosed.  
Analyses must be stratified by age. In particular, there is a need for prospective studies of neonates 
with NRDS. In addition, it might be helpful to combine information into clinical prediction scores, 
using state of the art approaches [16]. Validity of the different clinical features is also likely to vary 
depending on the population under evaluation. For instance, positive and negative predictive values 
of the symptoms depend strongly on the prevalence of the disease in the referral population and 
will be poorer in populations with a lower prevalence (i.e. in primary or secondary care compared to 
PCD referral centres). Sensitivity and specificity (shown in the table) do not depend on prevalence. 
Nevertheless the mix in PCD phenotypes, and therefore the usefulness of different symptoms for 
prediction of PCD is likely to differ between patients attending specialised clinics (e.g. ENT, 
pulmonology, cardiology). For instance, while chronic cough will not distinguish between patients 
with and without PCD in a pulmonology clinic, chronic ENT symptoms will not be distinctive in an 
ENT clinic, where (nearly) every patient has these complaints, and cardiac defects will not distinguish 
in a cardiology setting.  Another factor to consider is that clinical features might differ between 
genetic variants (e.g. patients with CCNO variants show no situs anomalies but increased female 
infertility), so results vary with differences in prevalence of specific mutations in the evaluated 
population.  Studies therefore must be done in specific health care settings and study populations, 
and consider age groups, sex, and genetic abnormalities.   
Summary 
Relevant literature answering our question was extremely scarce (two papers only, of which one 
reported only on situs inversus), and results did not allow to take severity of symptoms into account 
or stratify by age. Overall confidence in their results is moderate mainly because diagnostic 
performance does not inform downstream consequences of further clinical management based on 
the assessment of these symptoms.  
Results suggest that clinical symptoms may help to distinguish between patients with and without 
PCD, but the positive predictive value (how many patients with a specific symptom do have the 
disease) of single symptoms is low. Instead, the combination of suggestive symptoms might 
discriminate better, but this needs further studies in different populations. 
Wet cough starting in early childhood has been used as the initial selection criterion in most PCD 
studies.  Therefore it has a low discriminative value due to its high prevalence in both PCD positive 
and negative individuals recruited to these studies.  
   
Nasal Nitric Oxide 
Summary of recommendations 
In patients suspected of having PCD, should nasal nitric oxide be used as a diagnostic tool? 
Based on MODERATE confidence in the evidence, we recommend that:  
1. Nasal nitric oxide measurement should be used as part of the diagnostic work-up of 
schoolchildren over 6 years and adults suspected of having PCD, preferably using a 
chemiluminescence analyser with a velum closure technique (strong recommendation).   
2. In children under 6 years suspected of having PCD, we suggest nasal nitric oxide 
measurement using tidal breathing as part of the diagnostic work-up (weak 
recommendation).  
Remark - we suggest that patients presenting with a strong clinical history should undergo further 
testing, even if nNO is normal (weak recommendation) 
Explanation of the diagnostic test 
Nasal nitric oxide (nNO) is extremely low in PCD when compared to healthy and disease controls, for 
unknown reasons [19]. The accuracy of nNO as a diagnostic test in PCD varies by type of analyser, 
sampling method and age of patient [20].   
Current guidelines recommend aspiration of gas from one nostril with gas entrained via the other 
naris to measure nNO using a stationary chemiluminescence analyser during a velum closure, such 
as breath hold or oral exhalation against resistance.  The reading should be obtained from a 
technically acceptable plateau reading[21].  Whilst measurement during velum closure by 
chemiluminescence analyser is considered the ‘gold standard’, this manoeuvre is not possible in all 
situations. In young children measurements during tidal breathing have been reported[22, 23].  
Electromechanical portable analysers [23] are used where stationary chemiluminescence analysers 
are not available.  There is currently no consensus over what threshold constitutes a positive or 
negative cut-off.  
Publication Study population 
(n=) 
Sampling method  
(n, threshold nl/min) 
Sensitivity (95% CI) Specificity (95% CI) 
Table 3. Summary of diagnostic accuracy of nasal nitric oxide (nNO) from measurements in 
consecutive patients suspected of PCD. 
Although analysers report readings in parts per billion (ppb), this is influenced by the machine 
sampling rate, so the concentration is converted to nanolitres/min (nl/min) by the formula 
nl/min=ppb x sampling rate in l/min. 
Review of evidence directly addressing the question “in patients suspected of having PCD, should nNO 
be used as a diagnostic tool?” 
Our search identified 98 studies, of which 23 met inclusion criteria for qualitative assessment. Of 
these, four papers (n=588 patients) assessed nNO in a cohort of patients suspected of PCD who 
eventually received either a positive or negative diagnosis, directly addressing the question (Table 3 
and Supplementary Table 4). The other 19 papers were excluded from informing the 
recommendations but contributed to the narrative review (Supplementary Table 5). 
Marthin et al. measured nNO during breath hold, exhalation against resistance and tidal breathing. 
Sensitivity ranged from 0.92 (for breath hold) to 1.0 (oral exhalation against resistance) and 
Marthin et al 
2011 [24] 
117 referrals  
PCD 14 
Breath hold (n=58, 52.5) 
Oral exhalation against resistance 
(n=37, 72.6)  
Tidal breathing (n=97, 47.4) 
 0.92 (0.62 to 0.998) 
1.0 (0.54 to 1.0) 
0.93 (0.66 to 0.998) 
0.96 (0.85 to 0.995) 
0.94 (0.79 to 0.99) 
0.80 (0.69 to 0.88) 
Leigh et al 
2013[25] 
155 referrals 
PCD 71 
Indeterminate 84 
Oral exhalation, velum closure 
(n=155, 77 ) 
0.99 (0.92 to 0.9996) 0.75 (0.64 to 0.84) 
Beydon et al 
2015[22] 86 referrals 
PCD 49 
Non-PCD 37 
Velum closure (n=74, 82.2 ) 
Tidal breathing – 5 peaks (n=86, 40) 
0.91 (0.79 to 0.98) 
0.90 (0.78 to 0.97) 
0.86 (0.68 to 0.96) 
0.97 (0.86 to 0.999) 
Jackson et al 
[26] 301 referrals 
PCD 34 
Non-PCD 267 
Velum closure (breath hold or oral 
exhalation) 
(n=301, 30) 
0.90 (0.74 to 0.98) 0.95 (0.90 to 0.98) 
specificity ranged from 0.80 (tidal breathing) to 0.96 (breath hold)[24].  Leigh et al developed a 
threshold of 77nl/min using data from a PCD specialist centre and then trialled this cut-off in 155 
consecutive patients at other sites. Comparing PCD positive to indeterminate patients provided a 
sensitivity of 0.99 and specificity of 0.75[25]. Lower specificity was because the diagnostic protocol 
only included electron microscopy and genetics, thus missing a number of true PCD cases 
(‘indeterminate’ rather than PCD negative). Beydon et al reported a sensitivity of 0.91 and specificity 
of 0.86 for velum closure (cut-off 82nl/min) and 0.90 and 0.97 for tidal breathing (40nl/min; mean of 
5 peaks)[22].  Jackson et al used a cut-off of 30nl/min, and reported sensitivity of 0.91 and specificity 
of 0.96 to distinguish 34 PCD positive from 267 PCD negative patients[26].  Further methodological 
details of these 4 studies are included in Supplementary Table 4. 
Overall confidence in this evidence is moderate mainly because diagnostic performance is not 
informative of downstream consequences of further clinical management 
Narrative review of additional evidence 
A number of studies that did not meet the inclusion criteria for making recommendations addressed 
important issues.  Several studies used alternative methods for nNO measurement that do not use 
the ATS/ERS guideline “gold standard” (velum closure, stationary analyser) [21].  Tidal breathing 
manoeuvres are useful, especially in those unable to perform a velum closure, but may be less 
discriminative.  Marthin et al’s study of consecutive referrals found breath hold sensitivity of 0.92 
and specificity of 0.96 compared to tidal breathing values of 0.93 and 0.80 (thresholds were breath 
hold – 52.5nl/min, tidal breathing – 47.4nl/min)[23]. Beydon et al, however, found increased 
accuracy of tidal breathing (37.9nl/min threshold; sensitivity 0.94, specificity 0.92) versus velum 
closure (82.2nl/min, 0.91, 0.86)[22]. Measurement using portable analysers was assessed in two 
case control studies.  Using a portable analyser, Marthin et al compared PCD patients to those with 
CF and healthy controls.  They found a 1.0 sensitivity and 0.95 specificity for breath hold (64nl/min 
threshold) and 1.0/1.0 for tidal breathing (43nl/min) [23].  Harris et al studied 13 PCD and 37 disease 
control/healthy patients using tidal breathing and a portable analyser with a cut off of 30nl/min.  
Sensitivity was 1.0 and specificity 0.95[27]. 
Measurement of nNO in young children is possible, however discrimination between PCD patients 
and controls is reduced as nNO is inversely proportional to age in healthy patients under 12 
years[28, 29]. One study showed that velum closure was possible in children as young as 3.9 years 
[20]. However the majority of very young children are unable to co-operate with velum closure and 
so tidal breathing measurements have to be used. The studies by Marthin et al and Beydon et al 
suggest that tidal breathing may produce similar accuracy to velum closure in adults[22, 23], 
however this has not been shown in children; Marthin et al’s study of 117 consecutive referrals of all 
ages, found that the false positive rate for children under 6 years using tidal breathing was 39%[23].  
There is increasing evidence that some genetic defects causing PCD with subtle beating defects may 
be associated with nNO levels within the normal range. This includes two studies of PCD individuals 
with mutations encoding radial spoke head proteins and one in PCD individuals with abnormal nexin 
link composition due to GAS8 mutations associated with nNO higher than that usually seen in PCD 
[30–32]. This may partially explain the variability of the results and low diagnostic performance of 
nNO in some studies   
Key unanswered questions and research needs 
Current evidence has shown that nNO is a useful test as part of the diagnostic process, however 
there is no consensus on appropriate thresholds.  Likewise, standardised protocols and thresholds 
need to be developed for tidal breathing, portable analysers and measurements and normative data 
in younger children, particularly those under 6 years of age.  Further work on genotype-phenotype 
correlation can help in interpretation of nNO levels in cases of diagnostic uncertainty in order to 
reduce the number of false negative test results.  There is no evidence that can lead us to 
recommend which patients with a normal nNO should be referred for further testing and this 
requires evaluation. 
Summary 
Nasal NO is a highly accurate test for PCD when measured via stationary chemiluminescence 
analyser using velum closure techniques with a sensitivity of 0.90-1.0 and specificity of 0.75-0.97.  
Tidal breathing technique or use of portable analysers are less sensitive and specific but may 
contribute to the diagnostic decision. Different studies have used different methods and cut-off 
values making it difficult to provide definite thresholds.  
Nasal NO is not sufficiently accurate to rule in or rule out PCD in isolation but considering that it is 
relatively easy to perform, non-invasive and affordable, the panel considered that it should be used 
as part of the diagnostic work-up of patients suspected of having PCD. 
 
 
  
High Speed Video Analysis 
Summary of recommendations 
In patients suspected of having PCD, should HSVA be used as a diagnostic tool? 
Based on LOW confidence in the evidence, we recommend: 
1. High speed video analysis, including ciliary beat frequency and beat pattern analysis, should 
be used as part of the diagnostic work-up of patients suspected of having PCD (weak 
recommendation).  
2. Ciliary beat frequency should not be used without assessment of ciliary beat pattern in 
diagnosing PCD (strong recommendation). 
To improve diagnostic accuracy of HSVA, CBF/P assessment should be repeated after ALI culture 
(strong recommendation). 
Explanation of the test 
PCD is related to abnormal ciliary function [33] which can be analysed ex-vivo by assessment of 
ciliary activity in respiratory epithelium from the nose or bronchus. Ciliated cells can be observed 
immediately after sampling[34–36] and again after a period of culture to differentiate PCD from 
secondary dyskinesia [37–40]. A video attached to a microscope records at high speeds (120 to 500 
fps), and is replayed slower (30-60fps) to review ciliary beat pattern (CBP) and measure ciliary beat 
frequency (CBF)[41].  Most studies have used analysis by expert microscopists, whilst several studies 
used computer analysis in an attempt to reduce subjectivity/ observer bias. High speed video 
analysis (HSVA) provides a permanent record that can be used for audit, expert advice, or research. 
Review of evidence directly addressing the question “in patients suspected of having PCD, should 
HSVA be used as a diagnostic tool?” 
Our search identified 113 studies, of which 30 met inclusion criteria for qualitative assessment. 
(Supplementary Figure 1). Two studies (n=650 patients) assessed HSVA in cohorts suspected of PCD 
who eventually received either a positive or negative diagnosis, contributing to the evidence for 
recommendations (Table 4). The other 28 papers did not meet the inclusion criteria for informing 
the recommendations, but contributed to our narrative review (Supplementary Table 6). 
 
Publication Study population Cilial assessment method  Sensitivity (95% CI) Specificity (95% CI) 
Papon et al 2012 
[42] 
25 referrals  HSVA beat frequency and quantitative 
measurements of beat pattern 
0.96 (0.89-0.98) 0.95 (0.91-0.98) 
(10 PCD positive) 
Jackson et al 2015 
[26] 
625 referrals 
(60 PCD positive) 
HSVA beat frequency and subjective 
pattern 
1.0 (0.94-1.00 ) 0.93 (0.91-0.95) 
 
Table 4. Summary of diagnostic accuracy of high-speed video analysis (HSVA) from evaluation in 
consecutive patients suspected of PCD. Two studies fitted the PICO and inclusion criteria. 
 
Papon et al. measured 12 parameters of ciliary beat pattern, including ciliary beat frequency. The 
distance travelled by the cilia tip weighted by the percentage of beating edges had the best 
sensitivity (0.96) and specificity (0.95) to distinguish 10 PCD positive from 15 PCD negative patients 
[42]. Using this parameter in 9 patients with previously inconclusive diagnoses, it was possible to 
support the diagnosis of PCD in 4 cases and exclude it in 2. Jackson et al. found a sensitivity of 1.00 
and specificity of 0.93 for the combination of ciliary beat frequency measurement and beat pattern 
evaluation in a cohort of 625 referrals, including 60 PCD positive [26]. 
Overall confidence in this evidence is low mainly because diagnostic performance is not informative 
of downstream consequences of further clinical management based on the assessment of HSVA and 
because of study limitations (HSVA was widely used as part of the reference standard and lack of 
blinding).” 
Narrative review of additional evidence 
To date, there is no standardised method for cell processing and analysis. Respiratory epithelium can 
be collected using brush, curette or forceps, usually from the nose[43]. Ciliary function varies under 
differing conditions, for example temperature and pH, with some centres measuring at 37oC[26, 40, 
42, 44] and others at lower temperatures[35, 37, 45]. This will affect ciliary function and all centres 
need to define their own normative data until a consensus is reached to allow standardisation of 
methods and reporting between centres. 
Equivocal results or abnormal results require repeat sampling or reanalysis following cell culture [38, 
40, 46, 47] since secondary defects are common. In a series of 712 patients, Jorissen et al assessed 
CBF and ciliary coordination in suspension culture (i.e. spheroids). Twenty percent of non-PCD 
(n=642) patients demonstrated abnormal ciliary activity before culture, but after culture 100% had 
normal ciliary activity. Conversely, in biopsies of PCD patients (n=70; evaluable in 56), 20% had a 
normal CBF and 10% had a coordinated ciliary activity before culture. After culture, a normal CBF 
was found in 7% of PCD patients but ciliary function was never normally coordinated, making this 
parameter more sensitive and specific than CBF measurement [47]. Hirst et al report CBF and CBP 
before and after air-liquid interface (ALI) cultures in 158 patients [40]. Before culture, most PCD and 
non-PCD patients exhibited a degree of functional ciliary abnormalities. After ALI-culture, normal 
CBP was observed in all non-PCD patients whilst in PCD patients, CBP was uniformly abnormal. 
Pifferi et al assessed the results of CBP and CBF analysis after suspension culture (i.e. spheroids) in 9 
subjects with inconclusive results on nasal brushings [36]. After culture, 4 patients had abnormal 
CBP suggesting PCD diagnosis, 2 had secondary dyskinesia CBP and 3 remained inconclusive. Culture 
techniques are limited by success rates ranging from 54-83% [26, 37, 40]. 
CBF measurement does not adequately differentiate PCD from non-PCD unless combined with CBP 
assessment.  Stannard et al found a sensitivity of 0.97 and a specificity of 0.95 for the percentage of 
dyskinetic epithelial edges whilst CBF alone only yielded a sensitivity and specificity of 0.87 and 
0.77[48]. Moreover, CBF may be slow, normal or increased in PCD depending on the genotype[49].  
Some ultrastructural defects and genetic mutations causing PCD may be associated with specific 
patterns of ciliary beating. In a cohort of 56 children, Chilvers et al reported virtually immotile cilia in 
patients with either a combined IDA and ODA defect or an isolated ODA defect, stiff beat pattern in 
patients with either an isolated IDA or radial spoke with an IDA defect, and circular beating cilia in 
patients with a ciliary transposition defect[44]. Raidt et al studied CBP according to the genetic 
variants of PCD[49]. Although numbers associated with some genes were extremely small, the data 
supports the linking of PCD causing-gene with particular CBPs: for cilia from patients with mutations 
in ODA causing genes (DNAH5, DNAI1, DNAI2, ARMC4), showed minimal residual movements. In 
patients with DNAH11 mutations (normal ultrastructure), cilia exhibited a hyperkinetic CBP with 
reduced proximal axonemal bending. Some genetic defects such as GAS8 mutations can result in so 
subtle defects hardly detectable by HSVM [30]. 
Key unanswered questions and research needs 
Current evidence suggests that HSVA is a useful test as part of the diagnostic process, but there is no 
consensus on appropriate cell processing and method of ciliary assessment. Likewise, standardised 
protocols and thresholds need to be developed for ex vivo analysis of ciliary beat pattern. Further 
work on genotype/ultrastructural-phenotype correlation can help in interpretation of HSVA 
parameters in cases of diagnostic uncertainty. 
Summary 
HSVA is an accurate test for PCD when performed by experienced observers combining ciliary beat 
frequency measurement and pattern analysis (sensitivity of 0.95-1.00 and specificity of 0.93-0.95). 
Culturing the respiratory cells may contribute to improve the accuracy of HSV, in particular to rule 
out false positives. 
HSVA is not sufficiently standardised to rule in or rule out PCD in isolation. Considering that optimal 
conditions in functional evaluation of cilia remains to be defined, the panel considered that HSVA 
should be performed by experienced staff as part of the diagnostic work-up of patients suspected of 
having PCD. This might impair the availability of the test in many centres. 
  
Transmission Electron Microscopy 
Summary of recommendations 
In patients suspected of having PCD, should TEM be used as a diagnostic tool? Based on LOW 
confidence in the evidence, we recommend: 
1. Ciliary ultrastructure analysis by transmission electron microscopy should be used as part of 
the diagnostic work-up of patients suspected of having PCD (strong recommendation). 
2. Further diagnostic investigations should be performed in patients with normal ultrastructure 
if the clinical history is strong (strong recommendation).1 
3. In patients with hallmark ciliary ultrastructure defects for PCD further confirmatory 
diagnostic investigations are not required2. (strong recommendation) 
Footnote: 1normal ciliary ultrastructure, as resolvable by transmission electron microscopy, does 
not exclude the diagnosis of PCD (16% PCD positive patients have TEM without a detectable 
defect);. 2patients with hallmark ciliary ultrastructure defects for PCD (absence of outer dynein 
arms, combined absence of inner and outer dynein arms, inner dynein arm absence combined 
with microtubular disarrangement), assessed by TEM, almost always have PCD (false positive 
results are very rare ≈0.7%) 
Explanation of the diagnostic test 
In 1976 Afzelius et al demonstrated that transmission electron microscopy (TEM) could be used to 
detect ultrastructural defects of cilia in patients with primary ciliary dyskinesia[33]. For many years 
subsequently TEM was considered the ‘gold standard’ diagnostic test for PCD.  However, several 
genetic studies have demonstrated that an increasing number of distinct genetic PCD sub-types  (e.g. 
due to DNAH11 mutations) cannot be diagnosed by TEM [50]. Thus, TEM cannot rule out PCD 
diagnosis. 
Respiratory epithelium is usually sampled from the inferior turbinate of the nose by brush or curette 
biopsy or from the lower respiratory tract during bronchoscopy.  The epithelium is chemically fixed 
with glutaraldehyde, processed and embedded into blocks which are sectioned with an 
ultramicrotome.  Staining with heavy metals (lead and uranyl) provides contrast. Assessment of cilia 
from healthy cells in transverse section is made using a transmission electron microscope[51, 52]. 
The number of cilia and cells analysed varies between centres; unless sufficient numbers are 
assessed, defects caused by mutations in genes which cause intermittent defects are likely to be 
missed. Considerable expertise is required to perform TEM and interpret results; expenditure for 
equipment and running costs are high. 
The normal ultrastructural ciliary arrangement in transverse section is a circle of nine microtubule 
doublets, each with a pair of dynein arms, plus a central pair of microtubules (Figure 1). There are a 
number of ultrastructural phenotypes associated with a diagnosis of PCD. The majority of cases are 
due to a lack of dynein arms; other defects include disorganisation of the microtubular doublets or 
loss of the central microtubular pair (Table 6). Some patients with PCD have apparently normal 
ciliary ultrastructure, as resolvable by TEM. Secondary ciliary dyskinesia can be associated with 
transient ultrastructural abnormalities, such as compound cilia, axonemal blebs or additional 
tubules, which must not be confused with PCD. 
 
Figure 1:  Diagram of normal ultrastructure of the ciliary axoneme in transverse section  
Figure 2: Electron microscopy images of PCD defects. A. Inner and outer dynein arm defect, B. Outer 
dynein arm defect, C. Inner dynein arm and microtubular disarrangement, D. central pair and 
transposition defect  
 
Review of evidence directly addressing the question “in patients suspected of having PCD, should 
TEM be used as a diagnostic tool?” 
We identified and screened 370 studies, of which 46 full texts were assessed for eligibility. Of the 17 
that met inclusion criteria for qualitative assessment (Supplementary Table 7), 11 papers (n=3200 
patients) assessed TEM in a cohort of patients suspected of PCD who eventually received either a 
positive or negative diagnosis, contributing to the evidence for recommendations (Supplementary 
figure 1).   
Tables 5 & 6 summarise the 11 studies addressing the question. The sensitivity calculated from each 
study ranged between 0.71 and 1.00 and the specificity between 0.92 and 1.00. There were five 
false positive patients in two studies. Papon et al identified two false positive results; one was a child 
with severe asthma without recurrent upper airway infection who had short or absent ODA 
concerning 44% of nasal cilia and 90% of bronchial cilia, the other an adult with situs inversus and 
nasal polyposis without lower airway symptoms who had absent IDA without microtubular 
disorganisation (pers comm).  Munkholm et al identified three false positives in individuals each 
eventually thought to have a secondary ciliary dyskinesia, two of whose clinical phenotype improved 
becoming asymptomatic and a third who had severe asthma [53]. Total specificity, when combining 
all 11 studies, was >0.99. 
Quality of evidence was rated low because diagnostic performance is not informative of 
downstream consequences of further clinical management and because of study limitations 
(frequent use of TEM in the reference standard and lack of bliniding).  However, the very low rate of 
false positives and the very high specificity of TEM led to strong recommendations. 
Publication Study Population (n) Conclusive 
diagnostic result 
reached  (n) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Jorissen et al 2000 [37] 812 468 0.71 (0.61-0.81) 1.0 (0.99-1.0) 
Pifferi et al 2007 [54] 64 62 0.75 (0.48 -0.93) 1.0 (0.93-1.0) 
Pifferi et al 2009 [39] 59 56 0.77 (0.50 -0.93) 1.0 (0.91-1.0) 
Hirst et al 2010 [55] 231 187 1.0 (0.88-1.0) 1.0 (0.98-1.0) 
Papon et al 2010 [56] 1149 793 0.82 (0.77-0.86) 1.0 (0.99-1.0) 
Olm et al 2011 [57] 24 24 0.92 (0.62-1.0) 1.0 (0.74-1.0) 
Papon et al 2012 [42] 34 28 0.83 (0.52-0.98) 1.0 (0.79-1.0) 
Shoemark et al 2012 [58] 1182 1031 0.88 (0.83-0.91) 1.0 (1.0-1.0) 
Hirst et al 2014 [40] 165 122 0.96 (0.87-1.0) 1.0 (0.95-1.0) 
Munkholm et al 2015 [53] 239 61 0.83 (0.61-0.95) 0.92 (0.79-0.98) 
Jackson et al 2015 [26] 868 368 0.79 (0.68-0.88) 1.0 (0.99-1.0) 
 
 
Table 5. Sensitivity and specificity of the 11 studies directly addressing the PICO question using 
transmission electron microscopy to diagnose PCD  
 
 Papon et al, 
2010 [56] 
n=190 
Stannard et 
al,  2010 [48] 
n=68 
Olin et al, 
2011 [59] 
n=155 
Shoemark et 
al, 2012 [58] 
n=214 
Boon et al, 
2014 [60] 
n=138 
Jackson et 
al, 2015 [26] 
n=57 
Total 
Isolated outer dynein arm 
defect 
33% 26% 54% 41% 59% 46% 44% 
Inner and outer dynein arm 
defect 
32% 34% 23% 24% 6% 39% 25% 
Inner dynein arm with 
microtubular disorganisation 
13% 6% 7% 9% 16% 9% 10% 
Isolated Inner dynein arm 
defect  
4% 21% 15% 13% 0% 0% 9% 
Central pair defect 19% 13% 1% 12% 14% 7% 8% 
Other* 
 
3% 
  
5% 
 
1% 
Total (n=) 190 68 155 214 138 57 
 
 
Table 6: Characteristics of the ultrastructural defects described in 9 studies directly addressing the 
PICO question using transmission electron microscopy to diagnose PCD. * Other defects reported 
include ciliary aplasia, disorientation and extra microtubules 
 
Narrative review of additional evidence 
Assessment of the proportion of TEM defects in patients with PCD was made following review of all 
manuscripts (post 1996) describing a cohort of more than fifty individuals [26, 42, 48, 58–60] (Table 
4). Outer dynein arm defects (26-59%) and combined outer and inner dynein arm defects (6-39%) 
were the most commonly observed. The recommendations below refer to common hallmark defects 
(absence of outer dynein arms, combined absence of inner and outer dynein arms, inner dynein arm 
absence combined with microtubular disarrangement). Isolated inner dynein arm defects by TEM 
are controversial. Several studies acknowledge that inner dynein arms are difficult to visualise by 
TEM [42, 61, 62]and repeat analysis has been recommended before confirming a diagnosis [63].  For 
central pair defects the ciliary defect is usually present in a minority of cilia making the diagnosis 
difficult especially since patients do not have situs inversus.   
Evidence for add on techniques to improve electron microscopy in the diagnosis of PCD was 
reviewed. Computer-assisted analysis has been reported to enhance the visualisation of dynein arms 
and consequently improve the sensitivity of electron microscopy [61, 62]. Electron tomography is an 
advanced TEM technique allowing visualisation of structures in three dimensions. A series of 
transmission electron microscopy images are acquired by tilting the specimen stage at regular 
increments around two perpendicular axes. Images from both tilt series are then aligned into a 
single three-dimensional high-resolution projection. If a structural feature is repeated within a 
tomogram, it can be enhanced through sub-tomographic averaging; a technique in which software 
extracts the chosen common features and makes comparison by cross-correlation. Electron 
tomography  has been shown to improve 3D visualisation and resolution of cilia allowing 
identification of patients with HYDIN and DNAH11 gene defects in a research setting [64]. The use of 
tomography for diagnosis has not been evaluated. 
Our evidence review considered only conclusive results. Reported rates of inconclusive results 
ranged from 1.7% to 28.6% [26, 37, 39, 58]. This was attributed to poor sampling technique or the 
presence of secondary changes to the cilia. Seven of the 11 studies reported measures to avoid 
sampling during or immediately after an upper respiratory tract infection to improve adequacy and 
minimise secondary ciliary ultrastructural change.  
Cell culture techniques that induce ciliogenesis from human biopsies are used in a number of PCD 
diagnostic centres.  Two techniques to induce basal cell proliferation and ciliated cell differentiation 
have been described for PCD diagnosis[37, 40]. Jorissen et al established a submerged culture 
technique [37] and the air-liquid interface technique was first described for PCD diagnosis by Hirst et 
al[40]. Both methods have shown that the TEM axoneme structure is conserved after cell culture in 
normal and PCD subjects, and they have been shown to reduce secondary damage [37, 40]. TEM 
following culture has the potential to aid diagnosis of reduced generation of multiple motile cilia 
[65]. 
Key unanswered questions and research needs 
Basic science research must improve the TEM technique and identify PCD in those with ‘normal 
ultrastructure’. The diagnostic community requires standardised protocols and consensus on 
terminology, especially regarding the number and proportion of cilia required to make a diagnosis. 
True relevance and prevalence of inner dynein arm and other rare defects needs confirming. 
Summary 
Transmission electron microscopy is a highly specific test to confirm a diagnosis of PCD and is a key 
part of the diagnostic work. However, some patients with PCD have apparently normal 
ultrastructure and therefore TEM should not be used in isolation to exclude a diagnosis.  
All 11 studies were retrospective analyses of cohorts of patients with clinical suspicion of PCD, the 
largest of which spanned time periods of twenty years[56, 58]. Further downgrading was due to use 
of TEM as the reference standard and lack of blinding, resulting in grading of evidence as low. 
 
 
  
Genetics 
In patients suspected of having PCD, should genotyping be used as a diagnostic tool? 
 
There were no studies that fulfilled inclusion criteria to answer this question.    
Explanation of the diagnostic test 
PCD is a genetically heterogeneous disorder. As with autosomal recessive disorders in general, 
disease is more likely in offspring from consanguineous relationships, and has a 1:4 probability from 
any conception where both parents are healthy carriers. To date, mutations in more than 30 genes 
have been reported to cause PCD (Table 7). A more detailed explanation of the PCD-associated 
genes is presented in the supplementary file.  
Gene Locus TEM finding IF finding 
DNAH5 [66] 5p15 ODA Absent DNAH5 and DNAH9. [67–69] 
DNAH11 [50] 7p15-21 Normal DNAH11 is absent in patients with DNAH11 loss-of function 
mutations. DNAH5 and DNALI1 present [70, 71] 
DNAI1 [72] 9p21-p13 ODA DNAH5 staining may be present proximally but absent 
distally. 
DNAH9 absent within the ciliary axonemes. [67, 68] 
DNAI2 [68] 17q25.1 ODA DNAH5, DNAI2 and DNAH9 absent or aberrant [68] 
NME8 (TXNDC3) [73] 7p14.1 ODA Not reported 
DNAL1 [74] 14q24.3 ODA Not reported 
CCDC151 [75] 19p13.2 ODA DNAH5, CDC151, CCDC114 and ARMC4 absent; DNALI1 
present. [75] 
CCDC114 [76] 19q13.33 ODA CCDC114 severely reduced, DNAH5 absent, DNALI1 
undisturbed [76] 
ARMC4 [77] 10p21 ODA Reduced ARMC4 staining along cilia; complete distal loss of 
DNAH5; DNAH5 only on proximal ciliary end; DNALI1 present. 
[77, 78] 
CCDC103 [79] 17q12 ODA+IDA DNAH5, DNAH9 and DNALI1 are missing or reduced in a small 
number of patients. [79] 
DYX1C1 (DNAAF4) [80] 15q21 ODA + IDA DNAH5, DNAH9 and DNAI2 absent [80]  
SPAG1 [81] 8q22 ODA + IDA Absent DNAH5 and DNALI1 [81] 
LRRC6 [82] 8q24 ODA + IDA LRRC6, DNALI1 and DNAI2 absent or very reduced [82–84] 
DNAAF2 (KTU) [85] 14q21.3 ODA + IDA DNAH5 and DNAI2 absent distally with some residual 
staining. 
DNAH9 and DNALI1 absent.[85] 
DNAAF1 (LRRC50) [86, 87] 16q24 ODA + IDA DNAH5, DNAH9 and DNALI1, absent [87] 
C21orf59 [88] 21q22.1 ODA + IDA Absent DNAH5 and DNALI1[88] 
DNAAF3 [89] 19q13 ODA + IDA DNAH5, DNAH9 and DNALI1 absent [89] 
ZMYND10 [84] 3p21.3 ODA + IDA Absent DNAH5, DNAI2 and DNALI1.[84, 90] 
DNAAF5 (HEATR2) [91] 7p22.3 ODA + IDA DNAI1, DNAH5 and DNALI1  absent, HEATR2 reduced [91, 92] 
HYDIN [93] 16q22 Normal/ subtle: 
increased frequency of 
transposition defects 
Normal IDA (DNALI1) and ODA (DNAH5) [93] 
RSPH1 [32] 21q22.3 Intermittent central 
pair/ transposition 
defects 
RSPH1 and RSPH9 absent; RSPH4A present [32, 94, 95] 
RSPH3 [96] 6q25.3 Intermittent central 
pair/ near absence of 
radial spokes 
RSPH3 and RSPH11 absent; RSPH1, RSPH4A, and RSPH23 
present (RSPH9 not reported). DNALI1 present. [96] 
RSPH9 [94] 6p21 Intermittent central pair 
defect/ transposition 
Absent RSPH9; RSPH1 and RSPH4A present. [94] 
RSPH4A [94] 6q22 Intermittent central pair 
defect/ transposition 
Absent RSPH4A, RSPH9 and RSPH1. [94] 
DRC1 (CCDC164) [97] 2p23 Normal/ subtle: N-DRC 
links missing with 
occasional MT 
disorganisation 
GAS8 and LRRC48 absent from ciliary axonemes. [97] 
GAS8 (DRC4)[30] 16q24.3 Normal/ subtly 
abnormal: increased  
frequency of MT 
misalignment 
DNALI1 and DNAH5 present; absent GAS8 [30] 
CCDC65 (DRC2) [98] 12q13.12 Normal/ N-DRC links 
missing with occasional 
MT disorganisation 
CCDC65 and  GAS8 reduced[98] 
CCDC39 [99] 3q26 MT disorganisation + 
IDA 
Absent CCDC39 protein. ODA normal distribution (DNAH5, 
DNAI2, DNAH9); DNALI1 (IDA) absent; GAS8  in cytoplasm but 
absent from axoneme [99, 100] 
CCDC40 [101] 17q25 MT disorganisation + 
IDA 
Absent CCDC39 protein; RSPH4A and ROPN1L/RSP11 present 
in axonemes [100, 101] 
RPGR#[102] Xp21.1 Variable Normal, DNAH5 and DNALI1 present  [103] 
OFD1* [104] Xp22 Unknown Not reported 
CCNO [65] 5q11.2 Reduction of cilia 
number 
DNAH5 present; rootletin mislocated in deeper regions of 
cytoplasm; CCNO not detectable [65] 
MCIDAS [105] 5q11.2 Reduction of cilia 
number 
MCIDAS, CCNO, DNAH5, CCDC39 and CCDC78 absent [105] 
Table 7: Overview of PCD-causing genes, and their associated findings by TEM and IF analyses. ODA: 
outer dynein arm; IDA: inner dynein arm; n-DRC: nexin link- dynein regulatory complex; #: retinitis 
pigmentosa usually detected in adult patients; *: rare syndromic phenotype 
To establish the genetic diagnosis, non-ambiguous biallelic mutations in autosomal recessive PCD 
and hemizygous mutations in X-linked PCD should be identified. The majority of reported mutations 
are nonsense, frameshift or splice mutations while missense mutations are identified in a minority of 
cases. Most of the mutations are private, but founder mutations (e.g. in DNAI1[106] and DNAH5[69]) 
and mutational hot spots (e.g. CCNO[107]) have been reported.   The ranking of the effect of the 
mutations should follow international recommendations [108]: benign (class 1), likely benign (class 
2), unknown significance (class 3), likely pathogenic (class 4), pathogenic (class 5).  
The associations between genotype and structural defects documented by TEM and/or IF are well 
established, but much less is known about gene: HSVA associations. With studies based on small 
numbers of patients and often limited number of videos per patient[49], there is insufficient data to 
correlate mutations within a gene with dyskinesia phenotype; our knowledge to date suggests that 
disease-causing mutations in DNAH5 are always associated with predominantly static cilia whilst 
mutations in different regions of DNAH11 can lead to either static cilia or hyper-frequent, stiff cilia 
[49, 109]. Therefore, to confirm the genetic cause of PCD, the ultrastructural defect and gene should 
correlate; in the future, we may be able to use gene mutation: ciliary pattern correlations as further 
support. 
In principle all DNA sequencing technologies can be applied for genetic testing in patients with a 
confirmed PCD or a high suspicion of PCD (further detailed in the supplementary file). However, due 
to the high number and the huge size of PCD genes high-throughput techniques are now widely 
used.  The yield of allele-specific approaches is low in PCD given the high genetic and allelic 
heterogeneity. Detected mutations should be confirmed by Sanger sequencing and checked for 
segregation in the parents. Genetic laboratories have to be aware that large heterozygous genomic 
deletions have been reported in PCD individuals that might be missed by DNA sequencing 
technologies. Homozygous and heterozygous intragenic large duplications and deep intronic 
mutations are also missed by sequencing techniques. The detection of intragenic deletions and 
duplications will benefit from the fine set up of targeted next generation sequencing (NGS) panels; 
however, this approach requires specific development and sensitivity assessment. All techniques, 
especially the second line approaches, benefit from the knowledge of the ultrastructural defect of 
the patient in order to assess the relevance of the molecular findings. The ≈30 PCD genes implicated 
to date encompass more than 700 exons and thus it is not unusual to identify a heterozygous variant 
in a gene that is obviously not responsible for the disease of the patient based on ultrastructural 
data. Cell and whole organism models can be used to confirm that a gene is disease-causing. 
Review of evidence directly addressing the question “in patients suspected of having PCD, should 
genotyping be used as a diagnostic tool?” 
Searches identified 462 studies, of which 95 met inclusion criteria for qualitative assessment 
(Supplementary Table 8). Most studies included patients with confirmed PCD with the aim of 
identifying novel genes rather than diagnostic cohorts. There were no studies that fulfilled the 
inclusion criteria for quantitative assessment. 
Narrative review of additional evidence 
In populations with confirmed or highly suspected PCD diagnosis, it is possible to identify genetic 
causation in 50-75% of cases [110, 111].  The sensitivity of genetic testing as a first line diagnostic 
test for PCD is currently unknown but is likely to be low. With the identification of further PCD genes 
and high-through put sequencing technologies, PCD genetic testing as “stand alone” test might be 
considered in the future. Genotyping is useful in instances where confirmation of the diagnosis is 
difficult by other approaches (e.g. DNAH11, CCNO, MCIDAS and RSPH genes mutations). The 
detection of bi-allelic disease-causing mutations in autosomal recessive PCD or hemizygous 
mutations in X-linked PCD is highly specific.        
Most studies to identify novel PCD gene defects used ultrastructural defects detected by routine 
TEM as the starting point for the genetics search, therefore the likelihood to identify mutations in 
PCD with ultrastructural defects is higher than in PCD devoid of ultrastructural defects. This 
underscores the need not to rely on TEM as the sole diagnostic test for PCD. 
 
Reports of mutations in specific genes typically relate to small numbers of patients and are not 
necessarily ethnically representative; the contribution of each gene should therefore be interpreted 
with caution. Studies testing for DNAH5 and DNAI1 mutation suggest that these mutations account 
for ~50-70% of cases of ODA defects[67, 69, 112, 113]. Mutations in CCDC39 or CCDC40[99–101, 
114]account for almost all PCD individuals with microtubular disorganisation and absence of IDA.  Of 
58 unrelated PCD patients with normal ultrastructure 22% had biallelic mutations in DNAH11[70]. 
Mutations in the genes encoding radial spoke head and stalk proteins (RSPH1, RSPH3, RSPH4A, 
RSPH9), HYDIN and nDRC proteins (DRC1, CCDC65, GAS8) can cause PCD with normal or subtly 
abnormal ultrastructure (Table 7); to date, the contribution of these genes to the prevalence of PCD 
has not been determined. 
A systematic population-based genetic Israeli study revealed that RGMC may be more frequent (6%) 
in their particular PCD populations than previously estimated [107]. 
Genetic analyses have shown that mutations in the RGMC genes CCNO and MCIDAS as well as the 
genes encoding radial spoke proteins (RSPH1, RSPH3, RSPH4A, RSPH9) and the CP associated protein 
HYDIN do not result in laterality defects. In addition so far all PCD individuals carrying biallelic 
mutations in genes encoding nDRC proteins such as CCDC164, CCDC65 and GAS8 did not exhibit any 
situs abnormalities. 
Given the large size of the regions sequenced in PCD patients, it is not unusual to identify one or 
several rare missense variants that are not linked to the disease. Great care should be taken to 
interpret those variants: it is important to perform segregation analysis for those variants and their 
interpretation can rely on expert labs. In some cases immunofluorescence microscopy (IF) has been 
proven to be a useful tool to determine pathogenicity of missense mutations in PCD individuals with 
mutations in RSPH4A and RSPH9 that encode radial spoke head proteins [94]. However, 
immunofluorescence analysis can be normal if the mutated protein is still expressed and correctly 
assembled within the axonemes such as reported for DNAH11 missense mutations [71].  
We did not find evidence to either confirm or refute genotyping as a diagnostic test for PCD. Whilst 
there is a need for evidence of the utility of genotyping in a diagnostic setting, Table 8 summarises 
the Task Force assessment of current published evidence in genetic testing in PCD. 
Key unanswered questions and research needs 
The role of genetic testing is not well defined in the PCD diagnostic pathway. We need studies to 
investigate the accuracy and limitations of genetics as a diagnostic tool for PCD. The standards for 
diagnostic testing for PCD need defining.  
Summary 
We were unable to determine the accuracy of genetics testing due to lack of suitable studies. 
Several studies have identified the genes responsible in patients with confirmed PCD, suggesting 
that genetic testing identifies the gene in approximately 65% of cases; this is likely to increase as 
more genes are identified. The question of diagnostic accuracy should be revisited as new data 
become available.   
 
 
 
Task force statements on genetic testing for PCD 
Whilst further evidence in a diagnostic setting is required, experts on the Task Force agreed: 
1. Genetic testing to confirm diagnosis can be performed in PCD individuals diagnosed by 
other means (e.g. HSVA, TEM, IF) or in individuals with high clinical suspicion for PCD 
(typical clinical findings, low nasal NO) and no availability of other investigations such as 
HSVA, TEM or IF. A negative genetic test does not exclude PCD. 
2. Genetic testing can also be performed to establish diagnosis in patients highly suspected 
of PCD and in whom HSVA, TEM or IF failed to confirm the diagnosis, as it can be the case 
for patients with DNAH11, CCNO, MCIDAS or RSPH gene mutations. 
3. Genetic testing and interpretation of results should follow national and international best 
practice guidelines [115, 116]. 
4. Genetic diagnosis has to be consistent with the clinical and TEM/IF/HSV phenotype, or 
diagnosis reconsidered if the picture is inconsistent. 
5. Allelic segregation analysis within the family (especially in both parents) is important to 
confirm the genotype in the probands (to differentiate between homozygosity and 
hemizygosity, and between compound heterozygosity and a complex allele). 
6. Genetic testing in probands and in their relatives is helpful for genetic counselling to 
inform reproductive choices.  
7. In the future genetic testing might be important for genotype specific therapy. 
 
Table 8.  Summary of the Task Force consensus on the published evidence on genetic testing in PCD 
diagnostics.  
Immunofluorescence 
In patients suspected of having PCD, should IF be used as a diagnostic tool? 
 
There were no studies that fulfilled inclusion criteria to answer this question.    
Explanation of the diagnostic test 
Labelling of ciliary proteins was developed to improve understanding of the impact of disease-
causing genes on ciliary proteins[117]. Specific antibodies with secondary fluorescent tags localise to 
proteins in human respiratory epithelial cells and are visualised by fluorescent or confocal 
microscopy. A number of antibodies against ciliary proteins are available including antibodies 
targeting the outer dynein arm, inner dynein arm, radial spoke head and dynein regulatory complex 
proteins. An example of this technique is shown in Figure 3. 
Respiratory epithelial cells in suspension are placed onto glass slides, air-dried and fixed. The cells 
are incubated with antibodies to ciliary protein not implicated in PCD (e.g. acetylated tubulin) to 
label the axoneme, combined with antibodies of interest produced in a different species (e.g. anti-
DNAH5 to identify outer dynein arm structures).  
 
Figure 3. Representative immunofluorescence images of healthy controls and patients with GAS8, 
CCDC39 and RSPH9 mutations leading to absence of the protein in the cilia.  Acetylated tubulin is 
used to stain the cilia and Hoechst 3342 to stain the nuclei.  Scale bar is 10μm. 
 
Review of evidence directly addressing the question “in patients suspected of having PCD, should IF 
be used as a diagnostic tool?” 
Our search identified 276 studies (Supplementary Figure 1). No studies reported use of IF antibodies 
in a diagnostic setting and we were therefore unable to establish the accuracy of IF as a diagnostic 
test.  Forty studies contributed to our understanding of the potential to use IF diagnostically, as 
summarized below (Supplementary Table 9).   
Narrative review of additional evidence 
Although the literature focuses on research to understand the downstream effects of mutations in 
PCD-related genes (Table 7), several centres now use IF to aid diagnosis[118]. This is likely to 
increase as more antibodies become available, and once data for the accuracy of the tests becomes 
available. In the two largest patient-based cohort studies, DNAH5 IF was tested in 16 PCD patients 
and a further 17 families who had ODA defects observed by TEM; mislocalisation of the protein was 
reported in all cases. Furthermore DNAH5 protein was present in patients with cystic fibrosis and in 
healthy controls [67, 69]. A number of studies have used IF to examine protein mislocalisation 
related to genetic mutations (Table 7), providing indicators to the antibodies that might be used and 
findings expected when IF is used as a diagnostic test. IF can identify mislocalisation of proteins in 
PCD patients with a range of mutations, providing information on the pathogenicity of a mutation 
[94]. However most manuscripts report IF findings from small numbers of patients for each gene and 
mutation specific findings are not yet known.  
With IF it is possible to identify almost all ultrastructural abnormalities detectable by TEM and also 
some cases where the TEM is apparently normal or subtly abnormal [30, 71, 94]. The sensitivity and 
specificity of IF is unknown but will reflect the combination and quality of antibodies; in the authors’ 
experience, a number of antibodies do not work and validation including appropriate disease and 
healthy controls is required before they are used diagnostically. IF analysis can be normal if the 
mutated protein is still expressed within the axoneme [71]. 
We did not find evidence to either confirm or refute IF as a diagnostic test for PCD. Whilst further 
evidence in a diagnostic setting is required, the summary of Task Force findings from published 
evidence are shown in Table 9. 
Key unanswered questions and research needs 
We need validation studies to investigate the accuracy and limitations of IF as a diagnostic tool for 
PCD in diagnostic cohort studies. Each applied antibody needs validation in studies including 
appropriate PCD, disease and healthy controls.  
Summary 
We were unable to determine the accuracy of IF testing due to lack of suitable studies. Task force 
experts agree IF can be useful in clinical settings. IF is cheaper and easier than other diagnostic tests, 
providing a potential test for resource-limited settings.  
 
Task force statements on IF testing for PCD 
Whilst further evidence in a diagnostic setting is required, experts on the Task Force agreed: 
1. IF is able to confirm pathogenesis of mutations (e.g. missense mutations in genes encoding 
radial spoke proteins). 
2. IF can detect PCD in some cases with normal ultrastructure or subtle ultrastructural 
defects. 
3.  IF can help establish the diagnosis of PCD in ODA, IDA, tubular disorganisation 
(CCDC39/CCDC40 mutations), central pair (genes encoding radial spoke proteins) and 
nexin link defects.  
Table 9. Summary of the Task Force consensus on the published evidence on immunofluorescence 
testing in PCD diagnostics.  
Confirming or Excluding a Diagnosis of PCD 
The Delphi Consensus Survey comprised four consecutive on-line surveys, each building on former 
rounds. The outcomes of each round are summarised in supplementary table 11. Experts from the 
ERS Task Force agreed (>80% of respondents) on the following, which enabled us to propose a 
diagnostic algorithm (Figure 4): 
Positive diagnosis: For patients with a supportive history of PCD, the following results are 
confirmatory of a positive diagnosis of PCD: 
 Hallmark ciliary ultrastructure defects for PCD (absence of outer dynein arms, combined 
absence of inner and outer dynein arms, inner dynein arm absence combined with 
microtubular disarrangement), assessed by TEM. 
 Non-ambiguous biallelic mutations in PCD causing genes. 
The task force did not reach consensus (80%) that any other test in isolation nor in combinations 
could provide a conclusive positive diagnosis. 
Highly likely diagnosis: In patients with a compatible history of PCD the following diagnostic test 
results make the diagnosis of PCD highly likely, but do not provide a definitive PCD diagnosis. 
 Very low nNO plus HSVA findings consistently suggestive of PCD (e.g. static cilia, circling) on 
three occasions. 
 Very low nNO plus HSVA findings consistent with PCD (e.g. static cilia, circling) following cell 
culture. 
If the diagnosis is ‘highly likely’ but not conclusive, patients should be told that the diagnosis is likely 
but given the limitations of diagnostic tests, the diagnosis is not 100% certain and might need 
confirmation when better tests become available. Patients should have other causes for their 
symptoms excluded and should be treated as if they have PCD. As new diagnostic tests become 
available further investigations should be offered.  
Excluding the diagnosis of PCD: The Task Force did not reach consensus (80%) that any single test 
nor combination of tests could exclude a diagnosis of PCD. However, based on the evidence 
reviewed they agreed that there are conditions under which the diagnosis is ‘extremely unlikely’. If 
the clinical suspicion is only modest and: 
 nNO is high/ normal plus normal HSVA, or 
 nNO is high/ normal plus normal HSVA following cell culture, 
the patient can be counselled that the diagnosis is extremely unlikely and that further testing is not 
warranted. If the clinical suspicion is very high (e.g. Kartagener’s syndrome, PICADAR score >10) 
current diagnostic tests are not sufficiently accurate to exclude a diagnosis.  
General statements: Members of the Task Force suggest that diagnostic tests should only be 
conducted in laboratories with expertise in the field. The results should be interpreted by specialists 
with expertise in PCD and the results explained to the patient and their non-specialist carers. 
Diagnostic tests for PCD are currently imperfect. As our understanding and techniques for PCD 
advance, patients with a high clinical suspicion or inconclusive test results can be recalled and 
offered repeat testing.  
A number of patients have diagnostic tests which do not satisfy the criteria for being labelled 
positive, ‘highly likely’ diagnosis or ‘extremely unlikely’. These patients should be considered 
inconclusive; further investigation and management should be determined by a specialist with 
expertise in PCD.   
Diagnostic Algorithm: Based on the culmination of evidence from the GRADE recommendations and 
the Delphi Consensus statement, the following step-wise approach to diagnostic testing can be used 
(Figure 4). Not all patients need to undergo all steps. For many patients, step 1 (nNO and HSVM) will 
provide a ‘highly unlikely’ diagnosis, and patients won’t need further investigations. Some patients 
should proceed to step 2 (TEM or cell culture with repeat HSVM). Genetics testing (step 3) may help 
make a diagnosis in patients where other tests have failed to provide a definitive diagnostic 
outcome.  Patients who remain ‘inconclusive’ could be recalled in the future as further tests become 
available. This approach will not be appropriate for all diagnostic services; local expertise and 
equipment should be taken into consideration.  
Step 1: nNO  + HSVA 
If both are entirely normal, the diagnosis of PCD is very unlikely and further testing can be avoided 
unless the clinical suspicion is particularly high.  
If nNO is low and/ or HSVA is abnormal: PCD is the likely/ possible diagnosis- repeat these step 1 
tests and proceed to step 2. 
Step 2: TEM  
If TEM is normal: consider genetics testing for genes associated with normal or subtle TEM defects 
and repeat HSVA following cell culture.  
If TEM shows ‘hallmark’ defects PCD is confirmed: consider genetics testing to further characterise 
the underlying defect.  
Step 3: Genetics and repeat HSVA +/- cell culture 
Further testing: In patients where the diagnosis is highly likely or remains inconclusive, further 
investigations such as IF or radioaerosol mucociliary clearance analysis might be used but the 
evidence is too limited for us to recommend them. PCD clinicians should consider recalling these 
patients for further testing in the future, as advances in PCD diagnostics are made. 
 
 
Discussion 
The ERS Task Force presents the first evidence based guideline for the diagnosis of PCD. This is 
timely, as new diagnostic tests (e.g. ciliary protein immunofluorescence and genetic testing), are 
increasingly deployed along with refinement of existing tests (e.g. EM tomography and 
computational averaging). As new evidence arises, the guideline will need revisiting. We have 
provided guidance on who should be referred for diagnostic testing. We have confirmed that no 
diagnostic test is perfect, and in the absence of a gold standard, access to a combination of tests is 
necessary. Using a modified Delphi approach we then used the evidence for individual tests to 
develop a diagnostic algorithm, providing the criteria to define patients as positive, ‘highly unlikely 
’extremely unlikely’ and inconclusive. 
The studies that contribute to the recommendations were all conducted in specialist PCD diagnostic 
centres. The tests are generally complex, requiring experienced scientists and clinicians to analyses 
and interpret results. Our findings therefore provide evidence for diagnostic centres with high 
throughput of samples, analysed by experienced technicians and with good quality control. New 
diagnostic centres will require support from experienced centres for training and ongoing quality 
control/ assessment. BEATPCD (http://www.beatpcd.org/ COST ACTION BM 1407) is coordinating a 
programme of research and training to improve the diagnosis and treatment of PCD. This includes 
provision of training schools, bursaries for short-term placements in specialist centres and 
networking for discussion of difficult and equivocal diagnostic decisions.  Together with the 
anticipated European Reference Network for PCD, the collaborative approach should drive up 
standards of diagnostic testing across Europe.   
Results from diagnostic studies are an indirect measure of the downstream consequences of the 
application of a test, and therefore the confidence in the test accuracy measures was judged at best 
moderate to low. Evidence from patients does not alter the strength of published evidence but was 
considered when deciding the strength of recommendations. The Task Force conducted a 
questionnaire survey of 352 PCD patients from 25 countries, and 20 in-depth interviews [7]. Patients 
told us that an accurate diagnosis was an important outcome, leading to a better recognition of their 
problems by physicians and access to effective treatment, thus improving their health and quality of 
life. 
Once the Task Force recommendations were agreed, a modified-Delphi survey was used to develop 
a consensus on diagnostic approach. Experts from the Task Force agreed that results from TEM and 
genetic testing can lead to a definite positive diagnosis. This provides a guide for future clinical trials 
as well as clinical care, with the caution that our definition will systematically exclude PCD patients 
with normal ciliary ultrastructure where the genetic mutations are not yet known. Furthermore, 
most of the Task Force (>50%) considered that the following combinations of tests could lead to a 
positive diagnosis, but we did not reach consensus (defined by >80%): Very low nNO PLUS hallmark 
HSVM consistently on two occasions; very low nNO PLUS hallmark HSVM following cell culture 
(supplementary table 11). We have also defined conditions where the diagnosis of PCD can be 
considered as ‘extremely likely’ and where diagnosis is ‘extremely unlikely’. Given the current 
evidence, it is not possible to exclude a diagnosis with 100% confidence, but we have defined 
situations where further testing can reasonably stop. We anticipate that as our understanding of 
PCD grows, new phenotypes for this highly heterogeneous condition will be described that might not 
be detected by current diagnostic tests.  
All studies that contribute to our recommendations were hampered by the lack of a gold standard to 
investigate the accuracy of individual tests. We therefore accepted manuscripts that constructed a 
reference standard from a number of tests (‘composite diagnostic outcome’) or used an imperfect 
test e.g. TEM as a surrogate [119]. Studies using TEM or genetics as the reference standard will 
systematically exclude PCD patients with normal ultrastructure or where the genetic mutation is not 
known. Additionally, some of the evidence was based on studies where the index test was included 
in the composite diagnostic decision. These important limitations present a strong risk of bias and 
may have over inflated or deflated the sensitivity and specificity that we report for each test. None 
of the diagnostic tests had internationally agreed standards for conduct or reporting. This resulted in 
disparity of methods between the studies that we reviewed. The Task Force suggests that the 
following need to be taken into consideration to advance our understanding of diagnostic tests for 
PCD: 
1. Methodologists should be involved in the design of future studies to investigate diagnostic 
accuracy of tests. Consideration is needed for the lack of a perfect reference standard. 
2. To allow comparisons between studies, international standards for conduct of diagnostic 
tests and reporting of results is needed. The standards should be evidence based.  
3. Reporting of the clinical phenotype of patients included in diagnostic studies should  be 
improved and standardized. 
4. Impact of a diagnosis on patient outcome and quality of life should be investigated. 
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Figure Legends 
Figure 1:  Diagram of normal ultrastructure of the ciliary axoneme in transverse section  
Figure 2: Electron microscopy images of PCD defects. A. Inner and outer dynein arm defect, B. Outer 
dynein arm defect, C. Inner dynein arm and microtubular disarrangement, D. central pair and 
transposition defect  
Figure 3.  Immunofluorescence microscopy can be used to identify structural defects of motile cilia 
and to aid diagnosis of PCD. Antibodies directed against the outer dynein arm heavy chain DNAH5 
(red, A) can be used to detect outer dynein arm defects caused by various genetic defects. 
Antibodies against DNAH11 (green, B) can detect DNAH11 loss-of function mutations that cause PCD 
with normal ultrastructure. The antibodies directed against GAS8 (red, C) can identify isolated 
defects of the nexin-dynein regulatory complex (C). Antibodies against CCDC39 (red, D) are used to 
detect defects of the 96nm axonemal ruler (D) caused by CCDC39 or CCDC40 mutations.  Anti- 
RSPH9 antibodies (red, E) can be used to identify various defects of the radial spoke head complex 
(E). Normal localisation of ciliary components is shown by co-localisation (yellow color) with ciliary 
axonemal markers such as acetylated tubulin (green in A,D,E), alpha/beta tubulin (red in B) or 
unaffected ciliary components (i.e. DNAH5, green in C). In contrast, absence of structural 
components involved in ciliary motility is shown by absence of the protein in mutant cells (lower 
panels in A-E). Nuclei are shown in blue. Scale bars represent 10µm.   
Figure 4. Following development of recommendations using the GRADE approach, a Delphi survey 
allowed us to propose a diagnostic algorithm for PCD. Not all patients need to go through all steps.  
Please see the text for details of the implications of each diagnostic outcome (positive, highly likely 
and highly unlikely), as well as the consequences for the many patients who will continue to have an 
inconclusive outcome using currently available diagnostic tests. Patients with uncertain outcomes 
should be reconsidered for further testing as advances in diagnostic tests are made.  
 
 
 
 
 
